Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
More News
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Zacks
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Zacks
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.
Zacks
Is it the Right Time to Add Phibro Stock to Your Portfolio?
PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.
Zacks
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Zacks
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
HIMS' top line is driven by demand for weight loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
Zacks
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
Zacks
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.